Akeso granted FDA Fast Track designation for bispecific antibody

By The Science Advisory Board staff writers

August 13, 2020 -- The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Akeso for Ak104, a bispecific antibody, as a monotherapy for the treatment of patients with recurrent or metastatic squamous cervical cancer.

Ak104 is a humanized immunoglobulin G (IgG1) tetrameric bispecific antibody drug candidate designed to preferentially bind to tumor infiltrating lymphocytes. It targets two immune checkpoint molecules -- programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) -- simultaneously. The antibody was developed using Akeso's proprietary Tetrabody technology platform. The therapy is currently undergoing phase Ib/II and phase II clinical trials in China and Australia for multiple indications.

Twist Bioscience, Seismic Bio partner to discover bispecific antibodies
Twist Bioscience and Seismic Bio have formed a partnership to discover and optimize antibodies to high-value immuno-oncology targets.
Zymeworks, Merck to develop multispecific antibodies
Merck has signed a research and licensing agreement to develop multispecific antibody therapeutic candidates using platforms from clinical-stage biopharmaceutical...
Innovent, Roche partner on cell therapies, bispecific antibodies
Innovent Biologics has entered into a research and development collaboration with Roche for multiple cell therapies and bispecific antibodies.

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
ESMO Virtual Congress 2020
September 14-29
Online
2020 ACCP Annual Meeting
September 20-22
Online
BioProcess International West
September 21-25
Online
BioProcess International
September 21-25
Online
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter